CN1374948A - 具有抗惊厥和抗焦虑活性的4－氨基－1－芳基－1,5－二氢吡咯－2－酮及其制备方法 - Google Patents
具有抗惊厥和抗焦虑活性的4－氨基－1－芳基－1,5－二氢吡咯－2－酮及其制备方法 Download PDFInfo
- Publication number
- CN1374948A CN1374948A CN00812985A CN00812985A CN1374948A CN 1374948 A CN1374948 A CN 1374948A CN 00812985 A CN00812985 A CN 00812985A CN 00812985 A CN00812985 A CN 00812985A CN 1374948 A CN1374948 A CN 1374948A
- Authority
- CN
- China
- Prior art keywords
- pyrrolin
- ketone
- base
- morpholine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000008569 process Effects 0.000 title abstract description 3
- 230000001773 anti-convulsant effect Effects 0.000 title description 5
- 239000001961 anticonvulsive agent Substances 0.000 title description 4
- 230000000949 anxiolytic effect Effects 0.000 title description 4
- 229960003965 antiepileptics Drugs 0.000 title description 3
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 19
- 230000036506 anxiety Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 206010015037 epilepsy Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 48
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- -1 pipecoline Chemical compound 0.000 claims description 9
- 150000003053 piperidines Chemical class 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- HMTBQDHXRQHMHW-UHFFFAOYSA-N N-(trifluoromethoxy)nitramide Chemical compound FC(ON[N+](=O)[O-])(F)F HMTBQDHXRQHMHW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 150000003335 secondary amines Chemical class 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 5
- JEGMWWXJUXDNJN-UHFFFAOYSA-N 3-methylpiperidine Chemical compound CC1CCCNC1 JEGMWWXJUXDNJN-UHFFFAOYSA-N 0.000 claims description 5
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 claims description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 5
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 abstract description 4
- CDCHBOQVXIGZHA-UHFFFAOYSA-N 1,2-dihydropyrrol-5-one Chemical class O=C1NCC=C1 CDCHBOQVXIGZHA-UHFFFAOYSA-N 0.000 abstract 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 abstract 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 6
- 229960003529 diazepam Drugs 0.000 description 6
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 5
- 229960003120 clonazepam Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 4
- 229960002225 medazepam Drugs 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical class CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000000985 convulsing effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19944332.7 | 1999-09-16 | ||
| DE19944332A DE19944332A1 (de) | 1999-09-16 | 1999-09-16 | Antikonvulsiv und anxiolytisch wirkende 4-Amino-1-aryl-1,5-dihydro-pyrrol-2-one und Verfahren zu deren Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1374948A true CN1374948A (zh) | 2002-10-16 |
Family
ID=7922190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00812985A Pending CN1374948A (zh) | 1999-09-16 | 2000-09-02 | 具有抗惊厥和抗焦虑活性的4－氨基－1－芳基－1,5－二氢吡咯－2－酮及其制备方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6500821B1 (pt) |
| EP (1) | EP1212297A1 (pt) |
| JP (1) | JP2003509407A (pt) |
| KR (1) | KR20020027657A (pt) |
| CN (1) | CN1374948A (pt) |
| AR (1) | AR025700A1 (pt) |
| AU (1) | AU7283000A (pt) |
| BG (1) | BG106437A (pt) |
| BR (1) | BR0013961A (pt) |
| CA (1) | CA2317257A1 (pt) |
| CZ (1) | CZ2002915A3 (pt) |
| DE (1) | DE19944332A1 (pt) |
| EE (1) | EE200200137A (pt) |
| HU (1) | HUP0202607A3 (pt) |
| IL (1) | IL147808A0 (pt) |
| MX (1) | MXPA02001370A (pt) |
| NO (1) | NO20021143L (pt) |
| SK (1) | SK3782002A3 (pt) |
| TR (1) | TR200200678T2 (pt) |
| WO (1) | WO2001019793A1 (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106008304A (zh) * | 2016-05-18 | 2016-10-12 | 湖北科技学院 | 一种1,3-二氢-2h-吡咯酮类化合物及其合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH543504A (de) * | 1971-03-25 | 1973-10-31 | Lonza Ag | Verfahren zur Herstellung 1-substituierter 4-Aminopyrrolin-3-one-(2) |
| US4511568A (en) | 1982-05-12 | 1985-04-16 | Ici Americas Inc. | CNS-Depressant pyrazolopyridines |
-
1999
- 1999-09-16 DE DE19944332A patent/DE19944332A1/de not_active Withdrawn
-
2000
- 2000-08-30 CA CA002317257A patent/CA2317257A1/en not_active Abandoned
- 2000-08-31 US US09/652,488 patent/US6500821B1/en not_active Expired - Fee Related
- 2000-09-02 JP JP2001523373A patent/JP2003509407A/ja active Pending
- 2000-09-02 MX MXPA02001370A patent/MXPA02001370A/es unknown
- 2000-09-02 AU AU72830/00A patent/AU7283000A/en not_active Abandoned
- 2000-09-02 HU HU0202607A patent/HUP0202607A3/hu unknown
- 2000-09-02 EP EP00960584A patent/EP1212297A1/de not_active Withdrawn
- 2000-09-02 SK SK378-2002A patent/SK3782002A3/sk unknown
- 2000-09-02 IL IL14780800A patent/IL147808A0/xx unknown
- 2000-09-02 BR BR0013961-0A patent/BR0013961A/pt not_active Application Discontinuation
- 2000-09-02 EE EEP200200137A patent/EE200200137A/xx unknown
- 2000-09-02 CZ CZ2002915A patent/CZ2002915A3/cs unknown
- 2000-09-02 WO PCT/EP2000/008572 patent/WO2001019793A1/de not_active Application Discontinuation
- 2000-09-02 KR KR1020027003491A patent/KR20020027657A/ko not_active Application Discontinuation
- 2000-09-02 CN CN00812985A patent/CN1374948A/zh active Pending
- 2000-09-02 TR TR2002/00678T patent/TR200200678T2/xx unknown
- 2000-09-15 AR ARP000104877A patent/AR025700A1/es unknown
-
2002
- 2002-02-26 BG BG06437A patent/BG106437A/bg unknown
- 2002-03-07 NO NO20021143A patent/NO20021143L/no unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106008304A (zh) * | 2016-05-18 | 2016-10-12 | 湖北科技学院 | 一种1,3-二氢-2h-吡咯酮类化合物及其合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0202607A3 (en) | 2003-05-28 |
| AR025700A1 (es) | 2002-12-11 |
| CA2317257A1 (en) | 2001-03-16 |
| CZ2002915A3 (cs) | 2002-06-12 |
| DE19944332A1 (de) | 2001-03-22 |
| NO20021143D0 (no) | 2002-03-07 |
| US6500821B1 (en) | 2002-12-31 |
| BR0013961A (pt) | 2002-05-21 |
| AU7283000A (en) | 2001-04-17 |
| BG106437A (bg) | 2002-09-30 |
| WO2001019793A1 (de) | 2001-03-22 |
| SK3782002A3 (en) | 2002-07-02 |
| HUP0202607A2 (hu) | 2002-12-28 |
| NO20021143L (no) | 2002-03-07 |
| EE200200137A (et) | 2003-04-15 |
| IL147808A0 (en) | 2002-08-14 |
| TR200200678T2 (tr) | 2002-07-22 |
| JP2003509407A (ja) | 2003-03-11 |
| EP1212297A1 (de) | 2002-06-12 |
| KR20020027657A (ko) | 2002-04-13 |
| MXPA02001370A (es) | 2004-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1071571C (zh) | 含有反胺苯环醇物质和乙酰氨基苯的组合物及其应用 | |
| CN100540001C (zh) | 包含止泻药和埃坡霉素或埃坡霉素衍生物的组合 | |
| DE60200492T2 (de) | Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen | |
| Intagliata et al. | Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6, 7-Dimethoxy-3, 4-dihydroisoquinolin-2 (1 H)-yl) butyl)-3-methyl-1 H-benzo [d] imidazol-2 (3 H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo | |
| KR20130045379A (ko) | 글리신 수송 억제제 화합물과 항정신병약의 조합물 | |
| AU2021215274B2 (en) | Targeted drug rescue with novel compositions, combinations, and methods thereof | |
| JP2008512462A (ja) | ナルメフェン及びそれの類似体を使用する疾患の処置 | |
| EP1076557A1 (en) | Ccr-3 receptor antagonists | |
| CA2575995A1 (en) | Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists | |
| JP4867123B2 (ja) | 神経因性疼痛治療剤および神経因性疼痛のモデル動物 | |
| TW201211022A (en) | Methods of use of cyclic amide derivatives to treat sigma receptor-mediated disorders | |
| CN1262271C (zh) | 用于预防或治疗精神病的氨基甲酸酯化合物 | |
| CN1161041A (zh) | 杂环稠合的类吗啡衍生物 | |
| CN105209445B (zh) | 治疗运动障碍和相关病症的方法 | |
| CN1642572A (zh) | 成胶质细胞瘤治疗剂 | |
| CN1374948A (zh) | 具有抗惊厥和抗焦虑活性的4－氨基－1－芳基－1,5－二氢吡咯－2－酮及其制备方法 | |
| KR20180103846A (ko) | 항불안제 제조시 치환된 신남아미드 유도체의 적용 | |
| Watanabe et al. | Effects on central dopaminergic systems of d-coclaurine and d-reticuline, extracted from Magnolia salicifolia | |
| AU704695B2 (en) | Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
| CN1230178C (zh) | 伴有前列腺肥大症的膀胱刺激症状治疗药 | |
| Enguehard-Gueiffier et al. | Recent progress in medicinal chemistry of D4 agonists | |
| CN1447809A (zh) | 神经变性疾病的预防和治疗药物 | |
| AU2015363757B2 (en) | Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists | |
| JPH02268168A (ja) | ベンゾジアゼピン | |
| CN1498109A (zh) | 膀胱感觉过敏治疗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |